Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dietary Management

Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings

After more than two years of pandemic restrictions, many Pharma leaders are itching to meet with their key opinion leaders (KOLs) face-to-face again, believing that’s what most KOLs want. It may...

Impetus Digital

- PMLiVE

imc Group announces its rebrand as SCIRIS

SCIRIS offer tailored healthcare communications, medical compliance and brand strategy

- PMLiVE

INTRODUCING SCIRIS

imc group reveals new brand identity

Porterhouse Medical Group

- PMLiVE

NHS England set to be first in world to eliminate hepatitis C by 2030

Deaths from the virus fell by 35% following an antiviral drugs deal worth almost £1bn

- PMLiVE

WHO and EC expand strategic plans to deliver better health security

The partnership will reinforce areas highlighted in the EU Global Health Strategy

- PMLiVE

Novartis announces positive phase 3 results for prostate cancer drug Pluvicto

The study met its primary endpoint of radiographic progression-free survival

- PMLiVE

FDA approves Rigel’s Rezlidhia for acute myeloid leukaemia

Phase 2 data showed a complete remission rate of 35% and median duration of 25.9 months

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Influenza – the risk to vulnerable populations

Why we can't get complacent about flu vaccination

- PMLiVE

World-first trial launches in UK to assess stem cell transplants as first-line MS treatment

The £2.3m StarMS study will compare AHSCT with four other drug treatments

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

GSK’s Jemperli shows promise in phase 3 endometrial cancer trial

An interim analysis noted the trial met its primary endpoint of progression-free survival

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links